Effect of aspirin in coronary artery bypass grafting

Area of Science:

• Cardiothoracic Surgery
• Cardiovascular Research
• Pharmacology

Background:

• Aspirin (ASA) is commonly used for cardiovascular prophylaxis.
• Its effect on perioperative outcomes in coronary artery bypass grafting (CABG) surgery requires further clarification.
• Understanding ASA's impact is crucial for optimizing patient management.

Purpose of the Study:

• To assess the influence of aspirin (ASA) therapy on postoperative outcomes in patients undergoing their first coronary artery bypass grafting (CABG) surgery.
• Key outcomes evaluated include blood loss, transfusion requirements, reoperation for bleeding, and hospital and intensive care unit (ICU) stay duration.

Main Methods:

• Prospective observational study conducted over a 3-month period at a teaching cardiothoracic center.
• Included 240 consecutive patients undergoing their first elective CABG surgery.
• Excluded patients with coagulation abnormalities or those on interfering medications, focusing on 144 eligible patients.

Main Results:

• No significant differences were observed in total mediastinal blood drainage between groups based on days free of ASA.
• Blood product usage, rates of reoperation for bleeding, and durations of ICU and hospital stay showed no significant variations.
• Aspirin therapy did not correlate with increased adverse bleeding events or prolonged hospitalizations.

Conclusions:

• In patients undergoing their first CABG without pre-existing coagulation issues, aspirin (ASA) therapy does not appear to elevate postoperative blood loss or transfusion requirements.
• ASA therapy did not demonstrate a significant impact on the need for reoperation due to bleeding.
• The duration of intensive care unit and hospital stay was not influenced by aspirin therapy in this patient cohort.